CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Xanthus Life Sciences, Inc., a
privately-held oncology drug development company, today announced that it has
changed its corporate name to Xanthus Pharmaceuticals, Inc. The name change
aligns the Company's corporate name with its strategic focus to build a
differentiated specialty pharmaceuticals business.
"The last two years' efforts have focused on the development of the
Company's clinical pipeline, which today includes two exciting compounds in
clinical development and a third expected to enter the clinic later this
year," stated Richard T. Dean, Ph.D., President and CEO of Xanthus. "2006
will be an important building year for the Company as we develop our rapidly
evolving pipeline and seek to in-license additional compounds to complement
our portfolio. As such, we felt a change in our corporate name to Xanthus
Pharmaceuticals, Inc. more appropriately describes our strategic focus."
About Xanthus Pharmaceuticals, Inc.
Xanthus Pharmaceuticals, Inc. is developing a portfolio of novel,
clinical-stage, small-molecule oncology candidates through a management team
whose accomplished track record encompasses all aspects of drug development,
from discovery through regulatory approval and commercialization. The Company
is applying its expertise both to advance its current pipeline and expand it
into indications of unmet medical need beyond oncology.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. --
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., Senior Vice President & CFO, Xanthus
Pharmaceuticals, Inc. -- john.mccarthy@xanthus.com or (617) 225-0522 x 125
SOURCE Xanthus Pharmaceuticals, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson, MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
John A. McCarthy, Jr., Senior Vice President & CFO, of Xanthus
Pharmaceuticals, Inc., +1-617-225-0522 ext. 125,
john.mccarthy@xanthus.com
|
